Department of Nuclear Medicine, the First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Tumori. 2021 Aug;107(4):282-291. doi: 10.1177/0300891620940382. Epub 2020 Jul 31.
Tumor immunotherapy has become one of the main treatments for tumors. Inhibition of the pathways involving programmed cell death receptor 1 (PD-1) and its ligand (PD-L1) has gained favor in anticancer therapy, and can effectively prolong the survival of patients with cancer; however, numerous patients have PD-1/PD-L1 inhibitor primary resistance. The efficacy of anti-PD-1/PD-L1 therapy is related to the host tumor microenvironment. Radiation therapy can promote the body's antitumor immunity, change the tumor microenvironment, and synergize with anti-PD-1/PD-L1 treatment. Preclinical and clinical trials have shown that PD-1/PD-L1 inhibitor combined with radiotherapy has a significant effect. We review the synergistic antitumor mechanism and clinical trials of radiotherapy combined with anti-PD-1/PD-L1 therapy.
肿瘤免疫治疗已成为肿瘤主要治疗方法之一。抑制程序性细胞死亡受体 1（PD-1）及其配体（PD-L1）相关通路在抗肿瘤治疗中受到青睐，能有效延长癌症患者的生存时间；然而，许多患者对 PD-1/PD-L1 抑制剂原发耐药。抗 PD-1/PD-L1 治疗的疗效与宿主肿瘤微环境有关。放射治疗能促进机体抗肿瘤免疫，改变肿瘤微环境，与抗 PD-1/PD-L1 治疗产生协同作用。临床前和临床试验表明，PD-1/PD-L1 抑制剂联合放疗具有显著疗效。我们综述了放疗联合抗 PD-1/PD-L1 治疗的协同抗肿瘤机制和临床试验。
